Tecan Appoints Mukta Acharya as Head of Life Sciences Business Unit
Männedorf, Switzerland, June 24, 2024 – Tecan Group (SIX Swiss Exchange: TECN) today announced that Mukta Acharya, currently President of Tecan Americas, has been appointed the new head of Tecan Group’s Life Science business unit and member of the Executive Committee. He will take up his new role on August 1, 2024.
Dr. Klaus Lunn, head of the Life Sciences business since 2017 and member of the Management Board since 2013, has decided to leave the company to pursue other career opportunities.
Dr. Achim von Leoprechting commented, “I am very pleased that Mukta Acharya will be taking on this important role. Promoting from within to such an important role is a testament to the strength of our management team. Mukta has had great success growing our US business and building strong organizations. She has extensive industry expertise, having held senior roles in market-leading organizations in the life sciences and broader healthcare markets. With her impressive track record and dynamic leadership style, I am confident that she will continue to drive growth and further enhance our competitive position.”
Mukta Acharya joined Tecan in July 2022 as President, Tecan Americas, responsible for the successful financial and market performance of the Life Sciences business unit in the company’s largest sales region.
Mukta Acharya joins Tecan from Thermo Fisher Scientific (NYSE: TMO), where she most recently served as vice president and general manager of the Single-Use Flexible Solutions business. In this role, she drove the strategic growth of the global business across multiple manufacturing sites and thousands of employees around the world. She also oversaw product management, marketing, engineering and business development across the organization’s various business units.
Mukta Acharya held leadership positions at CVS Health (NYSE: CVS) from 2010 to 2018, most recently as Director, Enterprise Product Innovation & Management, and prior to that worked in management consulting.
She holds a Bachelor’s degree in Mechanical Engineering from India and a Master’s degree in Engineering Management from Dartmouth College in the US.
Under Klaus Lunn’s leadership, the Life Science business unit has achieved significant growth and successfully navigated the challenges posed by the COVID-19 pandemic. The Tecan Board of Directors and CEO would like to express their sincere gratitude to Klaus Lunn for his dedicated and key role in the development of Tecan’s Life Science business and wish him all the best for the future.
About Tecan
Tecan (www.tecan.com) improves people’s lives and health by enabling its customers to scale healthcare innovations globally, from life sciences to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in the development and production of OEM instruments, components and medical devices sold by its partner companies. Founded in Switzerland in 1980, the company has more than 3,500 employees and has manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in more than 70 countries. In 2023, Tecan’s sales were CHF 1,074 million (USD 1,194 million, EUR 1,108 million). Tecan Group’s registered shares are traded on the SIX Swiss Exchange (TECN, ISIN CH0012100191).
For more information:
Tecan Group
Martin Brundle
Senior Vice President, Corporate Communications & Investor Relations
Phone: +41 (0) 44 922 84 30
Fax: +41 (0) 44 922 88 89
Investor Relations
Tecan
Attachments
